✦ LIBER ✦

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors

✍ Scribed by Robert J. Motzer; Karen Cooper; Nancy L. Geller; David G. Pfister; Shiow-Yun Lin; Dean Bajorin; Howard I. Scher; Harry Herr; William Fair; Michael Morse; Pramod Sogani; Willet Whitmore; George J. Bosl

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 536 KB
Volume: 65
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

VAB-5 combination chemotherapy in progno

VAB-5 combination chemotherapy in prognostically poor risk patients with germ cell tumors

✍ Davor Vugrin; Willet F. Whitmore; Robert B. Golbey 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 429 KB 👁 2 views

Forty-four patients with nonseminomatous germ cell tumors with "poor prognostic features" were entered on the VAB-5 regimen and 38 are evaluable. VAB-5 represents an intensified version of the VAB-4 protocol. Poor prognostic features were considered to be bulky metastases (>5 cm in diameter), palpab

Serum tumor markers and patient allocati

Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors

✍ George J. Bosl; Nancy L. Geller; Dean Bajorin 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

The allocation of patients with advanced germ cell tumors (GCT) to different treatment programs based on clinical characteristics is standard in the design of clinical trials today. Studies have shown that substantial differences exist between entry criteria and that these differences could influenc

High-risk germ cell tumors in men high r

High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide

✍ Douglas W. Blayney; David A. Goldberg; Lucille A. Leong; Kim A. Margolin; Jerome 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Combination Chemotherapy With Vinblastin

Combination Chemotherapy With Vinblastine, Bleomycin, Cisplatin, and Etoposide (VBPE) in Children With Primary Intracranial Germ Cell Tumors

✍ Chang, Te-Kau ;Wong, Tai Tong ;Hwang, Betau 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB

## Abstract We have treated 13 children with primary intracranial germ cell tumors with the combination of vinblastine, bleomycin, cisplatin, and etoposide, the so‐called VBPE regimen in the past seven years at one institution. The clinical diagnosis of these children were: three germinomas, seven

High dose chemotherapy with ifosfamide,

High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults

✍ Jean-Pierre Droz; Pierre Biron; Jean-Pierre Lotz 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

Prognostic risk factors that identify pa

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis

✍ Axel Heidenreich; Isabell A. Sesterhenn; F. Kash Mostofi; Judd W. Moul 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Background: The purpose of this study was to develop a reliable model to identify clinical stage i nonseminomatous germ cell tumors (nsgcts) associated with low risk or high risk for occult retroperitoneal metastasis, so that the model could be used to customize the therapeutic approach for pati